In conclusion, several independent studies convincingly demonstrate that artemisinins treatment is an efficient method to reduce the level of Aβ and amyloid plaques, as well as tau hyperphosphorylation, in different AD mouse models, mimicking different stages of the disease, although the range of these reductions did not exceed 40–50% in either study. This evidence concerns the gene MAPT and Alzheimer disease.